Yabao Pharmaceutical announced that its wholly-owned subsidiary, Yabao Pharmaceutical Sichuan Pharmaceutical, received a drug registration certificate for levocetirizine hydrochloride oral solution from the National Medical Products Administration on July 31, 2026. The specifications include 75 milliliters to 37.5 milligrams and 150 milliliters to 75 milligrams, classified as a chemical drug category 3. The company's cumulative research and development investment reached 5.006 million yuan. The company stated that this approval will help improve its product portfolio and enhance market competitiveness, and it will actively promote production and market launch going forward. However, uncertainties remain in research and development as well as sales, and investors are advised to be aware of the risks.
Yabao Pharmaceutical Group Co LtdSubsidiary obtained drug registration certificate for levocetirizine hydrochloride oral solution, enhancing product portfolio and market competitiveness.